FDA’s Kweder Among Witnesses At Senate Drug Safety Hearing March 1
This article was originally published in The Pink Sheet Daily
Executive Summary
The Office of New Drugs deputy director could discuss implementation of the new Drug Safety Oversight Board. Other witnesses at the Health Committee hearing include former FDA advisor Gottlieb, Zuckerman Spaeder partner Schultz.